Edwards Lifesciences announced strong financial results for the third quarter of 2026, with sales beating expectations to reach $1.72 billion, a 10.5% increase year-over-year. This strong financial performance prompted the company to raise its annual growth forecast for the third time this year.
Technical and Clinical Growth Drivers
This growth is mainly attributed to the transcatheter aortic valve replacement (TAVR) segment, which generated sales of $1.24 billion. The company's CEO, Bernard Zovighian, noted that the positive results of the PROGRESS clinical trial, presented at the Transcatheter Cardiovascular Therapeutics conference, represent a turning point in how patients with moderate aortic stenosis are managed.
The Sapien 3 device demonstrated superiority over traditional clinical surveillance, reinforcing the shift toward proactive medical intervention before a patient's condition worsens to heart failure. Changes in national coverage policies by the Centers for Medicare & Medicaid Services (CMS) also contributed to expanding patient access, particularly for those suffering from severe asymptomatic stenosis.
What Does This Mean for Patients and the Medical Sector?
These developments underscore a shift in medical practice from passive surveillance to proactive intervention backed by technical evidence. For patients, this means the potential to receive treatment at earlier stages, reducing the risk of severe health deterioration. For the company, expanding the FDA-approved medical indications for the Sapien 3 device strengthens its position in a market that remains undertreated.
For their part, analysts view the stability of the company's TAVR business as primarily dependent on increasing procedure volume, with significant growth opportunities remaining in an under-penetrated market. The company also recorded notable growth in the mitral and tricuspid therapies segment, raising its sales forecast for this sector to between $780 million and $790 million.